Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: medication for triple negative breast cancer

PROVIDER: PRJNA780375 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16944716_1.fastq.gz	Fastqsanger.gz
	SRR16944716_2.fastq.gz	Fastqsanger.gz
	SRR16944717_1.fastq.gz	Fastqsanger.gz
	SRR16944717_2.fastq.gz	Fastqsanger.gz
	SRR16944718_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Shin_2018_EGFR-PYK2-c-Met interaction network_model

Project description:Systems modelling of the EGFR-PYK2-c-Met interaction network predicted and prioritized synergistic drug combinations for Triple-negative breast cancer

2024-09-02 | BIOMD0000000826 | BioModels

Mus musculus

Project description:Murine triple negative breast cancer

| PRJNA393706 | ENA

Project description:Triple-negative breast cancer sequencing

| PRJNA479973 | ENA

Identification of Prognostic Genes for Recurrent Risk Prediction in Triple Negative Breast Cancer Patients in Taiwan

2012-02-02 | GSE33095 | GEO

Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing

Project description:Twenty-four triple-negative breast cancer and 14 adjacent normal tissues were collected from breast cancer patients during surgeries at National Taiwan University Hospital (NTUH, Taipei, Taiwan). All triple-negative breast cancer samples were invasive ductal carcinomas (IDC) and were negative in immunohistochemical statuses of ER, PR, and HER2 receptors, as confirmed by professional pathologists. Treatment procedure of all patients followed the National Comprehensive Cancer Network (NCCN) guideline. All samples were neoadjuvant-free and were collected before systemic chemotherapy treatments. Written informed consent was obtained from all patients who participated in this study. Using human tissues for research in this study was approved by the institutional review board at NTUH. A novel set of 25-miRNA signature identified in this study was able to effectively distinguish between triple-negative breast cancer and adjacent normal tissues. Moreover, we documented the first evidence of seven polycistronic miRNA clusters preferentially harboring deregulated miRNA genes in triple-negative breast cancer.

2015-03-01 | GSE40049 | GEO

Identification of Prognostic Genes for Recurrent Risk Prediction in Triple Negative Breast Cancer Patients in Taiwan

Project description:Discrepancies in the prognosis of triple negative breast cancer exist between Caucasian and Asian populations. Yet, the gene signature of triple negative breast cancer specifically for Asians has not become available. Therefore, the purpose of this study is to construct a prediction model for recurrence of triple negative breast cancer in Taiwanese patients. Whole genome expression profiling of breast cancers from 185 patients in Taiwan from 1995 to 2008 was performed, and the results were compared to the previously published literature to detect differences between Asian and Western patients. Pathway analysis and Cox proportional hazard models were applied to construct a prediction model for the recurrence of triple negative breast cancer. Most expression data of samples (181/185) were reanalyzed from previous studies already uploaded to GEO (see "reanalysis of" links below). Four additional gene expression profiling data of triple negative breast cancer sample were added to this study.

2012-02-02 | E-GEOD-33095 | biostudies-arrayexpress

FOXC1 in triple negative breast cancer

Project description:FOXC1 in triple negative breast cancer

| PRJNA882754 | ENA

Homo sapiens

Project description:Heterogeneity of triple-negative breast cancer

| PRJNA381463 | ENA

Homo sapiens

Project description:Yale Triple Negative Breast Cancer Cohort

| PRJNA201430 | ENA

Project description:Triple-negative breast cancer sequencing data

| PRJNA863222 | ENA